Threshold for Improvement in Insulin Sensitivity with Adolescent Weight Loss - 22/08/13
, Lorraine E. Levitt Katz, MD 1, 2, Reneé H. Moore, PhD 3, Melissa S. Xanthopoulos, PhD 4, Chanelle T. Bishop-Gilyard, PsyD, MS 4, 5, Thomas A. Wadden, PhD 5, Robert I. Berkowitz, MD 4, 5Abstract |
Objectives |
To assess the association of weight loss and insulin sensitivity, glucose tolerance, and metabolic syndrome (MS) in obese adolescents following weight loss treatment, and to determine the threshold amount of weight loss required to observe improvements in these measures.
Study design |
A randomized, controlled behavioral weight loss trial was conducted with 113 obese adolescents. Changes in fasting insulin, homeostasis model assessment of insulin resistance, whole body insulin sensitivity index (WBISI), body mass index (BMI), and MS criteria were assessed at baseline and at month 4.
Results |
There was significant improvement in all measures of insulin sensitivity at month 4. Mean fasting insulin dropped from 22.3 to 16.6 μU/mL (P < .0001). Homeostasis model assessment of insulin resistance decreased significantly from 4.9 to 3.7 (P = .001) and WBISI increased significantly from 2.87 to 3.98 (P < .0001). An 8% reduction in BMI led to a significant improvement in WBISI (P = .03) and was the optimal threshold. Fewer individuals met criteria for MS after weight loss (P = .0038), although there were no significant changes in the individual features of the syndrome.
Conclusions |
In this trial, weight loss at month 4 was associated with improved insulin sensitivity in obese adolescents. An approximate decrease in BMI of 8% was the threshold level at which insulin sensitivity improved. As more weight loss programs are designed for obese adolescents, it will be important to have reasonable weight loss goals that will yield improvements in metabolic and cardiovascular disease risk factors.
Le texte complet de cet article est disponible en PDF.Keyword : BMI, CD, HDL, HOMA-IR, MS, OGTT, WBISI
Plan
| Supported by National Institutes of Health (DK054713, K24-DK065018, and T32-DK63688-09) and National Center for Research Resources (UL1RR024134). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. Unilever (London, United Kingdom) provided SlimFast for the study. The authors declare no conflicts of interest. |
|
| Registered with clinicaltrials.gov: NCT0021217. |
Vol 163 - N° 3
P. 785-790 - septembre 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
